Venturi Wealth Management LLC Has $156,000 Stake in Biohaven Ltd. (NYSE:BHVN)

Venturi Wealth Management LLC increased its position in Biohaven Ltd. (NYSE:BHVN) by 19.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,117 shares of the company’s stock after purchasing an additional 500 shares during the period. Venturi Wealth Management LLC’s holdings in Biohaven were worth $156,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SpiderRock Advisors LLC bought a new position in shares of Biohaven in the third quarter valued at $620,000. VELA Investment Management LLC lifted its position in Biohaven by 25.6% in the 3rd quarter. VELA Investment Management LLC now owns 17,530 shares of the company’s stock valued at $876,000 after acquiring an additional 3,572 shares in the last quarter. US Bancorp DE lifted its position in Biohaven by 57.1% in the 3rd quarter. US Bancorp DE now owns 2,173 shares of the company’s stock valued at $109,000 after acquiring an additional 790 shares in the last quarter. Values First Advisors Inc. acquired a new position in Biohaven during the 3rd quarter valued at about $78,000. Finally, Cadent Capital Advisors LLC purchased a new stake in shares of Biohaven in the third quarter worth approximately $1,771,000. Institutional investors own 88.78% of the company’s stock.

Biohaven Stock Performance

BHVN stock opened at $49.08 on Thursday. The stock has a fifty day moving average of $47.77 and a 200-day moving average of $40.82. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The company has a market capitalization of $4.64 billion, a price-to-earnings ratio of -5.25 and a beta of 1.31.

Wall Street Analysts Forecast Growth

BHVN has been the topic of several analyst reports. TD Cowen lifted their target price on Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partners lifted their price objective on shares of Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Bank of America increased their target price on shares of Biohaven from $52.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $59.00 price target on shares of Biohaven in a report on Tuesday, September 24th. Finally, Jefferies Financial Group began coverage on shares of Biohaven in a research note on Monday, September 16th. They issued a “buy” rating and a $57.00 price objective for the company. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $63.42.

Insider Buying and Selling at Biohaven

In other Biohaven news, Director John W. Childs bought 21,052 shares of Biohaven stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the purchase, the director now directly owns 21,052 shares of the company’s stock, valued at approximately $999,970. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Gregory Bailey bought 5,000 shares of the business’s stock in a transaction on Tuesday, September 24th. The stock was acquired at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the purchase, the director now directly owns 1,620,071 shares in the company, valued at $71,590,937.49. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John W. Childs purchased 21,052 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the transaction, the director now owns 21,052 shares of the company’s stock, valued at approximately $999,970. The disclosure for this purchase can be found here. Insiders own 16.00% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.